literature

SARS_CoV_2 mutation literature information.

Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein.

PMID: 34463219 2021 Journal of biomolecular structure & dynamics

Introduction: The top-binding ligands were additionally screened against biologically significant SARS-CoV-2 mutations occurring in the RBD of the S protein such as N501Y, E484K, K417N/T, A475V, I472V, L452R, V483A, F490L, S477N and N439K along with the United Kingdom, South African and Brazilian SARS-CoV-2 variants.

Method: Using the same PDB ID, the SARS-CoV-2 variants (N501Y, E484K, K417N/T, A475V,

A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels.

PMID: 34531417 2021 Scientific reports

Method: The following proteins were purchased from Sino Biological (Beijing, China): SARS-CoV-2 recombinant Spike RBD wild type, RBD (S477N), RBD (Y453F), RBD (K458R), RBD (F342L), RBD (V367F), RBD (N354D), RBD (A435S), RBD (V483A), RBD (W436R), RBD

Review of the mechanisms of SARS-CoV-2 evolution and transmission.

PMID: 34545334 2021 ArXiv

Introduction: We noted that L452R, V483F/A, E484K/Q, F486L, F490L/S, Q493K/R, and S494P could disrupt Eli Lilly mAbs.

Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency.

PMID: 34572486 2021 Biomolecules

Discussion: Global data analysis shows that infectivity strengthening and virion stable mutations are on the rise (especially the frequency of S477N, N439K, V483A, and V367F), clearly indicating the natural selection of mutations with stronger transmissibility.

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies.

PMID: 34642465 2021 Scientific reports

Result: The mutagenesis results obtained by mutating these three viral spike amino acids into the reported variants (V483A/F/G/I/L, F486I/L/S, and Y489C/F/H/S, respectively) ultimately confirm the minor role played by these residues at the SARS-CoV-2 RBD/LY-CoV555 mAb binding interface.

Result: led to the following list of naturally occurring mutations at the SARS-CoV-2 spike protein residues contacting the LY-CoV555 mAb: E484A/D/G/K/Q/R/V, Q493H/K/L/R, S494A/P/R/T, L452M/Q/R,

PMID: 34696404 2021 Viruses

Abstract: In the case of prolonged infections' mutations (long-term SARS-CoV-2 infections), V483A (0.009%) was found to be dominant followed by Q493R (0.009%), while other mutations were found in less than 0.007% of the studied sequences.

Result: Country-wise, V483A mutation was found only in the USA (63/300280 sequences) and the UK (11/178878 sequences).

Result: During this period, the prevalence of Q493R, Q493K, E484A and T470N increased by 0.004, 0.001, 0.003 and 0.001% points, respectively, while the prevalence of V483A and T415A decreased by 0.01 and 0.005% points, respectively.

Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants.

PMID: 34880635 2021 Infection and drug resistance

Table: V483A

Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka.

PMID: 35243004 2021 Wellcome open research

Result: Of these, five (S477N, E484K, E484Q, S494L, S494P) were found in viruses circulating in Bengaluru, and the amino acid replacement V483A was from an imported case.

Discussion: All nine amino acid changes, namely N440K, S477N, V483A, E484K/Q, F490S, S494L/P, N501Y are associated with immune escape.

SARS-CoV-2 genomic surveillance in Costa Rica: Evidence of a divergent population and an increased detection of a spike T1117I mutation.

PMID: 33905892 2021 Infection, genetics and evolution

Result: In addition, no structural variants in the receptor-binding domain (RBD) of the Spike protein (N439K, T481I, V483A, E484E, N501Y nor G476S) were identified.

Comprehensive annotations of the mutational spectra of SARS-CoV-2 spike protein: a fast and accurate pipeline.

PMID: 32954666 2021 Transboundary and emerging diseases

Table: V483A

Browser Board

Co-occurred Entities

Filtrator